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science & society T he new field of synthetic genetics has made significant advances during the past four years, both to create artificial and modified nucleic acids, and to investigate their structural and functional properties. This rapid progress promises to improve our understanding of the origins and fundamental basis of life, and to enhance the application of this knowledge in the search for new therapeutic drugs. So far, synthetic genetics has been confined largely to modifying the naturally occurring nucleic acids, DNA and RNA, in order to understand how molecules have evolved to store information, catalyse chemical reactions and replicate themselves; developments that might have been the precursors to life on Earth. In doing so, the field has coined the slightly misleading term 'XNA', to describe chemically modified nucleic acids. The name suggests that the only variable is the sugar, represented by the letter X, whereas in fact, modified nucleic acids can be synthesized from the two naturally occurring ones by modifying any of the three components: the nitrogencontaining nucleobases that pair with each other, or the sugars and phosphate groups that form the backbone of the molecule (Fig 1) . Moreover, as Phil Holliger, a pioneer in the field from Cambridge University in the UK, explained: "in addition, different modifications-and the density with which these modifications are introduced-can greatly affect the resulting XNA properties."
Holliger's team has focused on creating an artificial version of RNA capable of copying information from DNA to XNA and back again. The challenge was to develop two sets of polymerase, one that could copy a gene from a DNA molecule to one of the new XNA molecules, and the other to copy it back into DNA. Holliger and colleagues focused on modifying the sugar component-identifying six different sugars that could replace ribose or deoxyribose-to demonstrate, in a landmark publication, that it is possible to generate artificial genetic polymers capable of both heredity and evolution [1] . Holliger likened the process to a retrovirus such as human immuno deficiency virus (HIV), whichcopies repeatedly between RNA and DNA. "We are now exploring some of those novel backbones to demonstrate that they can serve not only as repositories of genetic information, but also as a source of functional molecules," he said. Such molecules could be used as ligands or aptamers that bind to specific targets to block undesirable pathways in a therapeutic application, or as catalysts or XNA enzymes to accelerate or enable target processes.
"I think this is the best work so far showing that it is possible to evolve the polymerases that normally work on DNA, so that they can work instead on these other related polymers," commented Jack T here is broad consensus that RNA was the first nucleic acid that evolved and that the earliest life forms relied on it both for storing information and catalysing its own synthesis, without help from either proteins or DNA. "Biology is telling us that RNA was the ancestor of DNA," commented Ramanarayanan Krishnamurthy, a synthetic organic chemist at the Scripps Research Institute in California, USA, studying the origins of life. Indeed, RNA is an extremely flexible molecule, capable both of encoding information and selfreplication. According to this view, DNA evolved later, as a superior and more stable long-term repository of genetic information, and proteins as more efficient and versatile catalysts of chemical reactions.
Krishnamurthy has speculated that rather than evolving along with early life forms, RNA might have even emerged first from the primordial chemical swamp as the progenitor of life. "RNA may be a chemical descendent, not biological descendent, of its own immediate ancestor," he said. TNA might well have been this ancestral molecule that led eventually to RNA. The sugar threose in the backbone has one carbon atom fewer than the ribose of RNA, and is simpler in the sense that it can be synthesized from a single starting material. At the same time, as the original work by Eschenmoser showed, TNA exchanges information with RNA by forming complementary strands, so could potentially have overlapped with it during early evolution. The crucial step for RNA to be used by living organisms would have been its ability to undergo tertiary folding into an organic molecule capable of binding to ligands and acting as an enzyme; a capacity that TNA lacks.
Krishnamurthy pointed out that as chemical evolution leaves no fossils, we will probably never resolve beyond all doubt what was the precursor of RNA. But at least work such as Holliger's is providing important clues. According to Szostak, the work on these XNA molecules suggests that "life does not use DNA and RNA out of chemical necessity, because apparently there are alternatives that could also work […] So we have to look elsewhere for an explanation of why biology uses DNA and RNA exclusively. One possible answer would be that the prebiotic chemistry of the early Earth led to RNA and DNA, and not to these alternative polymers. Alternatively, it could be that life began multiple times, using different polymers, but 'our' form of life won out, either because DNA and RNA are better, or because of some historical accident that led to alternative forms of life being extinguished."
Szostak's team has been probing pre biotic evolution by building simple protocellsessentially just RNA and XNA molecules inside a membrane-that self-replicate and evolve without requiring any other enzymes. In addition to investigating the chemical origins of life on Earth, there is great interest in identifying whether XNAs could be fundamental candidate molecules for life elsewhere in the universe. "The question is how you would identify alien life when you see it," Krishnamurthy said. This relates closely to the question of the origin of life on Earth, as it involves and identifies particular molecules and the underlying chemical environment that are conducive to the emergence and evolution of life. "The next step might be to further explore the connection between the structure of molecules able to support darwinian evolution on the one hand, and prebiotic chemistry on the other hand, to guess what kinds of genetic molecules will be encountered in the first alien species that we come across, perhaps in a NASA mission to Mars," commented Steven Benner, Director of the Westheimer Institute at the Foundation for Applied Molecular Evolution at the University of Florida, USA. B ack on Earth, XNA is also providing insights into the detailed molecular chemistry of DNA and RNA, some of which Benner claims has been taken too much for granted. "We all grew up memorizing the Watson-Crick double helix without giving it much thought," he said. "The bases were abstracted as cutouts, while the sugar and phosphate backbone was viewed just as a scaffold with very little impact on the base pairing that is central to genetics." But this view has turned out to be overly simplistic. Benner credits Eschenmoser for being the first to show that modifying the sugars or phosphates in the backbone totally changes the recognition ability of the molecule, which is crucial for its role in genetics.
Benner's own pioneering work was to create an expanded genetic alphabet by increasing the number of letters in the genetic code from the naturally occurring four to 12, and developing from it a working genetic system [4] . This work has already resulted in diagnostic applications to measure accurately the level of HIV and hepatitis B virus (HBV) infection, which can be used to determine the best way of managing these diseases in patients [5] .
"In a sample of blood taken by a doctor from a patient, one generally must detect very small amounts of material," Benner explained. "For example, 1 ml of blood might contain 10 virus particles, weighing approximately one billionth of one billionth of a gram. This means that the assay must be very sensitive." Polymerase chain reaction is one way to achieve high sensitivity by amplifying the viral DNA, but it is difficult and expensive to avoid contamination from the host's DNA or RNA. Therefore, some way of separating the viral DNA and RNA from that of the host is required, which in turn necessitates a molecular recognition process. The problem is that any method based on DNA tends to recognize falsely some sections of the patient's DNA, within which the sequence is quite similar to that of the virus.
Benner's solution was to tag the HIV or HBV with nucleic acids in a modified branched-DNA assay by using the expanded genetic code, which could be more easily separated from the patient's DNA and RNA. "Here, we would tag the HIV or hepatitis virus with a sequence today built not from GACT, the standard bases, but rather from GACTSBPZ, a sequence that contains some of our extra bases," Benner explained. "A virus particle, one of 10 in a millilitre, having a tag DNA with the sequence GACTSBPZ, would bind to a complementary sequence attached to a spot on the glass slide having the sequence CTGABSZP, since in our expanded DNA alphabet, Z binds to P and B binds to S." X NA-based therapeutic applications could also circumvent the crucial problem of delivery that plagues RNA-based therapies. In particular, short interfering RNA holds great therapeutic potential as it can interfere with gene expression and block undesirable pathways implicated in disease. But to reach targets inside a cell, RNA must penetrate the cell membrane and avoid degradation by the ribonuclease of the host; a problem that has so far thwarted most attempts to use RNA therapeutically. The earliest successful application of an XNA in this capacity [6] was a drug called pegaptanib, licensed by Eyetech Pharmaceuticals and then acquired by Pfizer, to treat neovascular (wet) age-related macular degeneration, which leads to progressive loss of central vision. The drug was an adapted version of an RNA that binds to the protein VEGF165, misregulation of which can cause abnormal blood vessel growth resulting in bleeding, scarring and irreversible damage to the photoreceptors.
Although pegaptanib was mainly developed as an XNA to evade degradation, work on XNA aptamers now focuses directly on their physicochemical properties, according to Vitor Pinheiro from Cambridge Biomedical Campus and co-author with Holliger of the work on sugar-modified XNAs. "For instance, HNA (anhydrohexitol nucleic acid) is not only nuclease-resistant, but can also withstand a wide range of pHs," he said. "As such, it may prove a useful XNA framework for the development of non-degradable aptamers for diagnostic purposes that can be recycled and reused." The chemical diversity of XNAs also opens up potential applications for nanoscale devices and structures outside biology, by positioning molecular components with near angstrom-level accuracy, just as in the construction of diagnostic aptamers.
Moreover, XNA-based therapeutics might not even have to cross the cell membrane, according to Benner, who argues that a large amount of RNA activity takes place outside cells and could be a more effective target for both RNA and XNA therapeutic drugs [7] . "Our proposal of extracellular RNA was, of course, rejected at the time," he commented. "However, as molecular […] . We believe that this is a much more direct application of nucleic acid chemistry to therapeutic goals, as it does not force the therapeutic agent to fight a membrane barrier that has evolved to prevent nucleic acids from crossing." This would open up a new area for RNA therapeutic research, given that extracellular microRNAs target messenger RNAs inside target cells through RNA interference pathways [8] .
Thus, because of its application to questions about the origins of life, the creation of new molecules that store information and self-replicate, or the development of new diagnostic and therapeutic applications, synthetic genetics involving artificial nucleic acids is becoming a versatile and important tool for molecular biologists.
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